Background The development of a rash has been retrospectively associated with increased
response and improved survival when treated with erlotinib at the standard dose of 150 mg …

7602 Background: Erlotinib is an orally EGFR TKI approved for the treatment of advanced
non-small-cell lung cancer. Its most frequent and specific toxicity is a rash which generally …

Background: To evaluate the anticancer activity of erlotinib in patients with previously
treated, advanced non-small cell lung cancer (NSCLC) whose dose is increased to that …

Abstract Erlotinib (OSI-774; Tarceva™) is an orally available, highly specific epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor. The results of 3 phase II studies with …

Background: Severe skin rash as toxicity of erlotinib has been reported in relation to better
response and survival. However, some patients require dose reduction due to skin toxicities …

Objective: To investigate the efficacy and adverse reaction of erlotinib as a single agent in
2nd and 3rd treatment of advanced non-small cell lung cancer (NSCLC) patients. Methods …

3045 Background: The recommended dose of the epithelial growth factor receptor (EGFR)
tyrosine kinase inhibitor E may have been based in part on skin rash grade, which may not …

Systematic treatment of advanced non-small cell lung cancer (NSCLC) includes targeted
treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). The …

Advances in the knowledge of tumor biology and mechanisms of oncogenesis has granted
the singling out of several molecular targets for non-small cell lung cancer (NSCLC) …

Purpose: Data from two large phase III studies were analyzed to characterize the correlation
between the occurrence of rash during treatment with the epidermal growth factor receptor …